Clinical Trial Update: An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH) [Phase 3]

View source ↗

Summary

Clinical trial update on Inhibikase Therapeutics' adaptive IKT-001 program for pulmonary arterial hypertension; the Phase 3 study is currently not yet recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• IKT-001 (IKT-001)

Snippet

Sponsor: Inhibikase Therapeutics | Conditions: Pulmonary Arterial Hypertension | Phase 3 | Status: NOT_YET_RECRUITING